Company profile: Tara Biosystems
1.1 - Company Overview
Company description
- Provider of predictive, in vitro human cardiac tissue models for drug discovery, safety assessment, and translational medicine, based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels, offering a high-fidelity solution.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tara Biosystems
Abcam
HQ: United Kingdom
Website
- Description: Provider of antibodies, proteins, and kits and reagents for life science research, validated for research use to support scientific studies and facilitate experimental procedures. Helps researchers with breakthroughs in cancer, neurological disorders, infectious diseases, and metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abcam company profile →
Algenex
HQ: Spain
Website
- Description: Provider of vector-based technologies to manufacture recombinant proteins via a baculovirus expression vector system, with applications in vaccines, diagnostic reagents, crystallography, HTS and therapeutic molecules. Offers CrisBio, animal vaccine development/production, and biocomponents for diagnostic and therapeutic markets in human and animal health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algenex company profile →
Ncardia
HQ: The Netherlands
Website
- Description: Provider of iPSC-based drug discovery platforms and predictive human cellular assay systems to expedite drug discovery from hit identification to lead optimization. Offers Ncyte Smooth Muscle Cells, Astrocytes, Endothelial Cells, Neural Mix, and vCardiomyocytes for in vitro modeling, safety and efficacy testing, cardiovascular and neural screening, pharmacology, toxicity, electrophysiology, and disease modeling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ncardia company profile →
Avalon GloboCare
HQ: United States
Website
- Description: Provider of precision diagnostics and clinical lab services—including bloodwork, anatomic pathology, urine/drug toxicology, STAT blood and genetic testing, pharmacogenomic (PGx) testing via real-time PCR, and PCR COVID-19 testing—delivered via its Lab Services MSO. Also offers the FDA Class I KetoAir Breathalyzer for ketosis detection and the QTY protein design platform (joint IP with MIT) for water-soluble cytokine receptor variants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avalon GloboCare company profile →
Nanna Therapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery platforms targeting fundamental cellular processes in age-related diseases. Offers the Nanoscale Medicines Discovery Engine for novel drugs addressing mitochondrial dysfunction and the Totally Integrated Medicines Engine (TIME), conducting 100 million phenotypic assays per hour to identify small-molecule leads for mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanna Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tara Biosystems
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tara Biosystems
2.2 - Growth funds investing in similar companies to Tara Biosystems
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tara Biosystems
4.2 - Public trading comparable groups for Tara Biosystems
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →